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Platelet activating factor (PAF)  ~ is a soluble molecule which is released from 
IgE-sensitized basophils upon stimulation with specific antigen or with anti-IgE 
antibody  (1-5).  It was shown  (1) to be the active principle  of a  cooperative in 
vitro allergic reaction involving rabbit platelets and basophils first described by 
Barbaro and Zvaifler in 1966 (6). Recently, PAF has been described in man (2, 7, 
8)  and  rats  (9),  and  a  material  similar  to  PAF  is  released  from  antigen- 
stimulated, IgE-sensitized rabbit lungs (10). PAF appears to be a low molecular 
weight phospholipid  (11) which binds avidly to albumin although retaining its 
biological activity in this form (2). 
PAF stimulates platelets to secrete in a noncytotoxic manner their content of 
vasoactive amines (1). It also initiates platelet aggregation (1, 2), apparently by 
a  direct and rather unique effect on the platelets rather than by a  mechanism 
involving released adenosine diphosphate (ADP), 2 which is only poorly released 
in this system (1). 
In the preceding paper (12), the nature of secretory reaction of rabbit platelets 
induced by PAF was characterized.  The secretion was shown to be extremely 
rapid and its extent was apparently  controlled by the concurrent induction  in 
the platelets of desensitization,  which was specific to PAF.  The temperature, 
pH, and cell density optima were determined and were found to be those of the 
blood, i.e., 37°C, pH 7.4, and 2.5 ×  108 platelets per ml. It was shown that all the 
platelets in a  preparation  responded to PAF. 
Since the desensitization  induced by PAF was shown to be specific for that 
stimulus  (12),  a  unique secretion pathway was implicated.  However, the simi- 
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from the National Institutes of Health, U. S. Public Health Service. 
1Abbreviations  used  in this paper:  AMP,  adenosine 5'-monophosphate; cAMP,  cyclic AMP; 
cGMP, cyclic guanosine 5'-monophosphate; DFP, diisopropylphosphofluoridate;  OMTI, ovomucoid 
trypsin inhibiter; PAF, platelet-activating factor; PGE1, prostaglandin E~; PMSF, phenylmethyl 
sulfonyl; SBTI, soybean trypsin inhibitor; TAMe, tosyl-l-arginine  methyl ester. 
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larities between the mechanisms of secretion induced in platetets by a variety of 
stimuli with the mechanisms of secretion in other cell types has been noted (13), 
and a general secretory pathway has been suggested. The experiments described 
herein were designated to examine this discrepancy and to further define some 
of the  cell-dependent  biochemical  parameters  of the  secretory process.  It has 
been determined that common elements do exist in the process of secretion, and 
that the unique characteristics of the PAF-induced platelet activation probably 
lie in the stimulus receptor interaction and in the nature of the serine protease 
which is activated. 
Materials  and  Methods 
PAF and platelets were prepared as described in the preceding paper (12). [:~H]serotonin  was 
incorporated into the platelets before washing and its release used to, indicate secretion (14). 
Platelet Secretion.  The  standard  reaction  mixture  contained  [3H]serotonin-labeled  washed 
platelets (final concentration 2.5  ×  108/ml),  PAF, and where indicated,  inhibitor, all in Tyrode's 
solution containing 0.25% gelatin in a final vol ofl ml (12). The plastic tubes were incubated for 15 
min at 37°C, centrifuged at 1,800 g  in the cold, and a 0.1-ml aliquot of the supernate removed for 
assessment of released [3H]serotonin.  For many experiments inhibitors were incubated with the 
platelets for 10 min at 37°C or room temperature before addition of PAF. Inhibition experiments 
were performed with concentrations of PAF previously determined by yield submaximal secretion 
(see Fig.  1).  All reactions were performed in duplicate,  and the secretion is expressed as mean 
percent [:~H]serotonin  released. Duplicates varied by less than 10%. The total ['~H]serotenin in the 
platelets was used for this calculation and was assessed by counting aliquots of platelets lysed with 
Triton  100. Radioactivity was  determined  in equal  parts  toluene  and  Aquasol  (New  England 
Nuclear, Boston, Mass.) in a  Beckman scintillation counter (Beckman Instruments  Inc., Fuller- 
ton,  Calif.).  Kinetic experiments  were  performed  as  described  in  the  previous paper  (12),  the 
reaction being stopped by dilution into cold EGTA-containing buffer. Experiments were repeated 
at least three times. 
Chemicals.  Diisopropylphosphofluoridate (DFP) was purchased from Sigma Chemical Co., St. 
Louis,  Mo.  and  dissolved in  Tyrode's gelatin  immediately before  use.  The  trypsin  inhibitors, 
soybean trypsin inhibitor (SBTI), (Sigma Chemical Co.), low molecular weight lima bean trypsin 
inhibitor  (LBT)  (Sigma Chemical Co.),  and ovomucoid trypsin  inhibitor (OMTI),  (Worthington 
Biochemical Corp.,  Freehold,  New Jersey),  esters  (Cyclo Sciences Inc.,  Palisades  Park,  N. J.), 
theophylline (Sigma Chemical Co.), cyclic 3'5'-adenosine monophosphate, cyclic guanosine mono- 
phosphate,  5'-adenosine  monophosphate,  (Sigma  Chemical  Co.),  phentolamine,  (Ciba  Corp., 
Summit, N. J.), propranolol,  (Ayerst Laboratories, New York), carbachol, acetyl choline, colchi- 
cine,  (Sigma  Chemical Co.),  and  epinephrine  (Parke,  Davis &  Co.,  Detroit,  Mich.)  were also 
diluted or dissolved in Tyrode's gelatin, the epinephrine and colchicine immediately before use. 
Phenylmethyl sulfonyl fluoride (PMSF, Sigma Chemical Co.) was dissolved at 50 mM in propylene 
glycol, prostaglandin  E  (generously supplied by Dr.  Pike,  UpJohn Co., Kalamazoo,  Mich.) was 
dissolved  in  ethanol  at  30  mM.  Cytochalasin  B  (ICI  Research  Laboratories,  Alderley  Park, 
Cheshire,  England)  was  dissolved  at  100  ~g/ml  in  ]/2oo dimethyl  sulfoxide  (DMSO)  Tyrode's 
mixture. It was ascertained that the solvents had neither an enhancing nor inhibiting action on 
PAF-induced secretion at the concentrations employed. 
Expression and Calculation of  lnhibition or Enhancement.  Experiments on different days were 
compared by calculating the inhibition of the percent that was secreted without the inhibitor. In 
this way,  differences between platelet preparations,  content of [:3H]serotonin,  etc.  can be mini- 
mized.  Generally,  the  percent  inhibition  or enhancement  +-  SEM of secretion by a  particular 
inhibitor has  been presented.  For most inhibitors,  the percent inhibition is independent of the 
amount of serotonin released in the control tubes  (i.e., without inhibitors),  and the validity of 
expressing the data this way is indicated by the reproducibility of the data.  In some experiments 
the inhibition is expressed as the mean pIso -+ SEM. This is defined as the negative logarithm of 
the  concentration  of inhibitor required  to give 50%  inhibition  and  allows a  direct comparison 
between inhibitors of a given class, e.g., small molecular weight esters. The pIso was determined 
from plots of percent inhibition versus inhibitor concentration. P~TER  M.  HENSON  AND  ZENAIDA  G.  OADES  955 
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Fro.  1.  Secretion of [3H]serotonin  from rabbit platelets induced by PAF or collagen. (a) 
Secretion from 2.5 x  l0  s platelets/ml incubated for 15 min at 37°C with increasing amounts 
of stimuli. The PAF preparation represents the dialyzed supernate from 1 ×  10?/ml sensi- 
tized rabbit leukocytes and contains 0.25% bovine serum albumin. The collagen concentra- 
tion was 350 ~g/ml. (b) Secretion expressed as a function of time of incubation. The reaction 
was stopped  by dilution with cold EGTA-containing buffer. 
Determinations of Cyclic AMP (cAMP).  Platelets were reacted with PAF (5 × 10~/ml with 200 
gl PAF) for varying times at 37°C. They were stopped  by extraction with 3 ml cold 5% trichlora- 
cetic acid (TCA). Excess TCA was removed by extraction with acidified ethyl ether. Subsequently, 
the aqueous portion was lyophilized and then resuspended in 0.05 M sodium acetate buffer, pH 6.2. 
The degree of recovery of cAMP through this procedure was ascertained by similarly extracting 
known, standard samples as controls. Alternatively, the secretion reaction was stopped by boiling 
for 20  min.  The precipitated protein  was  removed by centrifugation,  and  the  supernate  was 
lyophylized and analyzed for cAMP.  Concentrations of cAMP were measured  according to the 
Schwarz/Mann radioimmunoassay procedure (assay kit, Schwarz/Mann, Orangeburg, N. Y.). A 
standard  binding  curve  was  prepared  using  known  amounts  of cAMP for each  experiment. 
Measurements of cAMP were performed in duplicate on duplicate experimental samples. 
Results 
The Involvement of Serine Proteases in PAF-Induced Secretion 
Experiments  designed to examine the potential  role of serine proteases  and 
cyclic nucleotides in the secretory process rely heavily on the use of inhibitors. 
Before the initiation of such experiments, therefore, the dose response and time- 
course of PAF-induced secretion  were determined.  While  these have been de- 
scribed  at length  in the preceding  paper,  they  are  also depicted  in  Fig.  1 for 956  SERINE  PROTEASES,  cAMP  IN  PAP-INDUCED  PLATELET  SECRETION 
direct reference. Inasmuch as some of the experiments involve a comparison of 
PAF-mediated and collagen-mediated secretion, these data are also included in 
Fig.  1.  For subsequent experiments, concentrations of PAF to give less than 
maximal secretion were chosen (see Fig. i a), and an incubation time of 15 rain 
was employed. Because secretion was normally complete in one minute, this 
proved  sufficient to  allow  completion  of secretion  even  when  substantially 
inhibited. 
We have suggested that activation of 'mediator' cells in general involves the 
activation of a precursor (zymogen) serine protease or serine esterase, which is 
then involved in the subsequent cell response (13). Experiments were initiated 
to extend this observation to PAP-induced secretion from platelets. 
THE  EFFECT OF  DFP.  DFP  is  an  irreversible  inhibitor of serine  proteases 
(esterases).  It  will  also  inhibit  the  potent platelet  activators  thrombin  and 
trypsin. As shown in Fig. 2, if DFP is present during the reaction of PAF with 
platelets, secretion is inhibited in a dose-dependent fashion. Since the inhibitor 
is irreversible, the possibility that the DFP inhibits preformed enzymes on the 
platelets or in the PAF preparations can be ascertained. Pretreatment of either 
platelets or PAP for 20 rain with DFP (at different concentrations) followed by 
washing or dialysis, did not alter their ability to interact and initiate secretion 
(Fig.  2).  These  data  suggest that the  PAP  directly or  indirectly activates a 
precursor serine protease in the platelet that only then becomes inhibitable by 
DFP, and that this protease or esterase is required for the secretion process. 
THE ACTION OF OTHER PROTEASE INHIBITORS.  Table I indicates the inhibition 
achieved with PMSF, another general inhibitor of serine proteases. Again, this 
is  dose  dependent  and  does  not  occur  if the  platelets  are  pretreated.  The 
inhibitor must be present during the secretory reaction, suggesting its action on 
the same serine esterase discussed above. 
The trypsin inhibitors SBTI, limabean trypsin inhibitor (LBTI), and OMTI 
were also found to be inhibitory. The inhibition found with these agents was 
highly variable,  perhaps  reflecting their  large  size  and  a  possible  variable 
ability to gain access to the putative protease.  Generally, 50% inhibition was 
achieved with concentrations varying from 10  -5 to 10  -4 M. 
THE EFFECT OF LOW MOLECULAR WEIGHT ESTERS.  The natural substrate for 
such  an  enzyme is  unknown.  However,  the  possibility that  synthetic small 
molecular weight amino acid esters could inhibit the secretion was investigated, 
both to provide some information about a  possible substrate and to add addi- 
tional support to the hypothesis of an essential role for an activatable esterase. 
Fig. 3 depicts the inhibition of secretion achieved with seven esters. The data are 
expressed as the pI~o, the negative logarithm of the ester concentration to give 
50% inhibition. A pIso of 4, for example, represents 50% inhibition with 1 ×  10  -4 
M ester. Of the esters examined, TAMe (tosyl-/-arginine methyl ester) was most 
inhibitory. LeuMe (leucine methyl ester) was not inhibitory at all and served as 
an  important  control  to  indicate  that  5  x  10  -2  M  or  more  ester  was  not 
necessarily inhibitory to  secretion.  Esters  with basic  and/or aromatic amino 
acids seemed most inhibitory, and  substitution of the  amino group of lysine 
methyl ester with an acetyl group rendered it ineffective as an inhibitor. Also 
shown in Fig. 3 is the inhibition due to the amino acids, e.g. tosyl-/-arginine, PETER  M.  HENSON  AND  ZENAIDA  G.  OADES  957 
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FIG.  2.  Inhibition of secretion with DFP. Platelets were pretreated for 20 min at 37°C with 
buffer or DFP, washed, and incubated for 15 min at 37°C with PAF (25 ~l) or PAF pretreated 
with DFP and dialyzed. 
TABLE  I 
Effect of PMSF on PAF-Induced Release 
Percent  Percent 
release sero-  inhibi- 
tonin  tion 
Platelets  +  PAF 
Platelets  +  PAF  +  PMSF 2.5  ×  10  -~ M 
5.0  ×  10  -4 M 
1.0  x  10  -:~ M 
Platelets pretreated  with  10  -:~ M  PMSF  +  PAF 
Platelets pretreated with propylene glycol +  PAF 
32.0  -+ 2.3 
20.4  _+  3.0  36 
14.2  -+  1.8  56 
7.6  _+  1.1  76 
39.5  -+  1.9  0 
40.1  _+ 2.3  0 
Pretreatment  was  at  37°C  for 20  rain  followed  by washing.  The  PMSF  was 
dissolved in propylene glycol at 5  ×  10  -2 M. Background secretion (PMSF, but 
no PAF) varied from 0.1 to 1.6%. 
which is seen to be much less inhibitory than the esterified form. Methanol (the 
other product of hydrolysis of the methyl esters) in similar concentrations is not 
inhibitory.  Taken together this indicates that  it is the ester that is inhibitory 
and suggests substrate inhibition  of a  cell-bound esterase. 
The Effect of Cyclic  Nucleotides and Neurohormonal Stimulation  on PAF- 
Induced Secretion 
Secretion from a wide variety of cells has been shown to be under the control of 
intracellular levels of cyclic nucleotides. This was investigated. 
THE  EFFECT  OF AGENTS  THAT INCREASE  INTRACELLULAR cAMP.  To  determine 
the role of cAMP in PAF-induced secretion, theophylline and prostagandin  El 
(PgE~) were examined for their effect. Both agents induce increases in cAMP in 
platelets  (see ref.  13), the former by inhibiting phosphodiesterase  (15) and the 
latter  by stimulating  adenylate  cyclase  (16).  PgE~  was  found to  be a  potent 
inhibitor  (50%  inhibition  at  about  10  -7  M,  Fig.  4).  Theophylline  was  also 
inhibitory,  although at much higher concentrations.  Dibutyryl cAMP and 3'5'- 4.0. 
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FIG. 3.  Inhibition of secretion with amino acid esters. Esters were incubated with PAF 
(25-50 ~tl) and platelets, and the inhibition of secretion assessed. The shaded portion of the 
column represents inhibition with the ester, and the open area represents inhibition with 
the native amino acid. The data represent the mean +_ SEM of at least three experiments. 
BAMe, benzoyl-/-arginine  methyl ester; TAMe, tosyl-l-arginine  methyl ester; PheMe, phen- 
ylalamine methyl ester; AGLMe, acetyl glycyl lysine methyl ester; ALMe, acetyl lysine 
methyl ester; LMe, lysine methyl ester; LeuMe, leucine methyl ester. 
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FIG.  4.  Inhibition of secretion by agents that increase cAMP. The inhibitors were incu- 
bated with the platelet for 10 min at 37°C before addition of the PAF. Control secretion (no 
inhibitor) was 35.4 +_ 4.3%. 
cAMP  itself were  shown  to be inhibitory, whereas  control compounds  5'-AMP 
and 2'3'-cAMP were without  effect. This is indirectly of additional interest,  as 
AMP has been demonstrated  to be an inhibitor of ADP-induced  platelet aggre- 
gation  (17). 
If increased  cAMP  levels are indeed inhibitory to  PAF-induced  secretion,  a 
synergistic effect between  PgE1  and theophylline  would be expected  (18).  This 
was shown  to be the case  (Table II). 
EFFECT OF ADRENERGIC  AGONISTS.  The cAMP  system is usually modulated 
by adrenergic stimulation. Adrenergic agonists and antagonists were therefore PETER M.  HENSON AND  ZENAIDA  G.  OADES 
TABLE II 
Synergistic  Effect of PgE~ and Theophylline  on Inhibition of 
PAF-Induced Release 
Percent in- 
Treatment of platelets*  Percent release  hibition 
No inhibitor  48.1  _+  2.3 
PgE] 5  ×  10 -~ M  33.7  _+  5.1  30 
Theophylline 10 -4 M  39.1  -+  3.7  18 
PgE~  +  theophylline  4.1  _+  1.0  92 
Buffer  2.3  -+ 0.5 
* Platelets incubated at 25°C with inhibitor for 10 rain before addition of 
PAF. 
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FZG.  5.  Enhancement of secretion by epinephrine. Platelets were incubated with epineph- 
rine or isoproterenol for 10 min at 37°C before addition of  PAF. At concentrations below 10 -4 
M, epinephrine did not itself induce secretion. 
examined for their effect on PAF-induced secretion.  Fig. 5 depicts the effect of 
epinephrine.  A potent enhancement is observed. That this observation was true 
enhancement was demonstrated by the failure of epinephrine alone in the same 
concentration to induce secretion. Fig. 6 shows that the enhancement is similar 
over the complete dose-response curve for PAF.  Epinephrine  usually exhibits 
both  a-  and  B-adrenergic  activity.  Isoprotereno],  predominantly  B  in  action, 
produces little effect on PAF-induced secretion, a mild enhancement is observed 
at 10  -4 M (Fig. 5). This suggests little effect of fl-adrenergic stimulation  (which 
usually stimulates adenylate cyclase and increases intracellular cAMP) in these 
platelets.  The effect of epinephrine  would therefore appear  to be due to its  a- 
adrenergic action in lowering the levels of cAMP and as a consequence, enhanc- 
ing secretion.  In  our experiments,  epinephrine  was  shown to reduce platelet 
levels of cAMP by more than 25%. 
Fig. 7 depicts the results of experiments to demonstrate the adrenergic action 
of epinephrine, showing inhibition of its enhancing effect with phentolamine (an 
a-blocker) and virtually no alteration of its effect with propranolol (a/3-blocker). 
DECREASE  IN  INTRACELLULAR cAMP DURING SECRETION.  The data described 
above suggested that  increased  levels of cAMP inhibited  secretion,  and  that 
decreased levels induced by the  a-adrenergic  action of epinephrine,  enhanced 960  SERINE  PROTEASES,  cAMP  IN  PAF-INDUCED  PLATELET  SECRETION 
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Fro.  7.  The effect of propranolol or phentolamine on epinephrine enhancement of PAF- 
induced secretion. Incubation conditions are the same as those of Fig. 5. The open areas of 
the columns represent control secretion in the presence of the drugs but in the absence of 
stimulus. The first column (dashed hatching) represents the effect of PAF on platelets in the 
absence of adding epinephrine. 
secretion. This would imply that if cAMP has any direct role in the PAF-induced 
secretion, its levels would be likely to decrease to permit the secretion to occur. 
To  test  this,  we  measured  directly  the  levels  of cAMP  during  PAF-induced 
secretion. As shown in Fig. 8, cAMP level did decrease in platelets stimulated 
with PAF. The rate of decrease was extremely rapid (less than 30 s), which is 
consistent with the rapid secretion induced by PAF  (see Fig.  1).  By contrast, 
collagen, which also decreases cAMP, does so more slowly (Fig. 8), which again 
correlates with its slower secretion rate  (Fig.  1). 
THE  LACK  OF  EFFECT  OF  CYCLIC  GMP  (cGMP)  AND  CHOLINERGIC  STIMULA- 
TION.  To examine  the possible role of cGMP  (often found to  antagonize  the 
action of cAMP), cholinergic agents and cGMP were examined in a wide range of 
concentration  for  an  effect on  PAF-induced  secretion  (Table  HI).  None  was 
found. The secretory process, therefore, does not appear to be modulated by the 
antagonistic action of cGMP and cAMP, but by cAMP alone. PETER  M.  HENSON  AND  ZENAIDA  G.  OADES 
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FIG.  8.  Changes in  the levels of cAMP during PAF-induced secretion. PAF induced a 
faster rate of cAMP decrease than did collagen which is consistent with a  faster rate of 
secretion. See Fig. 1. 
The Effect of Colchicine and Cytochalasin B. Another system suggested to be 
of importance in the secretory process is that of the contractile elements of the 
cell (see 13). Microtubules play an important cytoskeletal role in the platelet (14, 
19), and their effect on PAF-induced secretion was accordingly examined using 
the inhibitor of microtubule assembly, colchicine. As shown in Fig. 9, colchicine 
is  an  effective  inhibitor  of  PAF-initiated  secretion,  50%  inhibition  being 
achieved  with  10  -4  M.  These  are  concentrations  similar  to those  required  to 
"disrupt" microtubules in platelets  (19,  20),  suggesting that this is indeed the 
mechanism of action. 
Microfilaments  comprised of the  contractile  protein thrombosthenin  can be 
observed in platelets underneath the plasma membrane  (21). Cytochalasin B is 
thought to disrupt microfilaments  (22),  although  it may have other actions as 
well. It was found to enhance the secretion from platelets stimulated with PAF 
(Fig.  8).  In  data not shown,  the enhancement  was seen over the entire  dose- 
response range of the PAF and could be demonstrated only if the cytochalasin 
was  present  during  the  reaction  and  not  if platelets  were  pretreated  with 
cytochalasin B  and washed. This is consistent with the known reversibility of 
the action of this drug (see 13). 
Discussion 
Secretion  from  platelets  stimulated  by  PAF  has  many  characteristics  in 
common with the secretory responses initiated by a number of other stimuli on a 
variety of cells (13). The secretion is modulated by intracellular levels of cAMP, 
controlled in turn by neurohormonal stimuli or prostaglandins,  Contractile and 
supporting elements within the cell are involved, and as shown previously (1, 
12), there is a requirement for calcium and platelet energy metabolism, presum- 
ably  supplying  ATP.  We  have  also  shown  a  requirement  for  an  activatable 
serine protease.  PAF is then a  unique activator of platelets, probably reacting 
with a unique cell surface receptor (12) and activating a unique serine protease 962  SERINE  PROTEASES,  cAMP  IN  PAF-INDUCED  PLATELET  SECRETION 
TABLE  III 
Lack of  Effect of Cholinergic Agents and cGMP on PAF-Induced 
Secretion 
Inhibitor 
Percent release of serotonin 
Without 
With PAF 
PAF 
None  35.9  2.2 
Carbachol  10  4  M  34.7  1.3 
10 -~  M  35.8  1.4 
10 -~  M  35.1  1.5 
10  '" M  34.3  2.2 
10 -~2 M  33.9  1.1 
Acetylcholine  10  4  M  33.5  1.7 
10 -~  M  33.1  1.0 
10 -~  M  32.9  2.4 
10-'" M  34.2  1.1 
10  ''~ M  35.5  1.5 
cGMP  10-:'  M  31.3  1.9 
10  '~  M  32.4  1.7 
10 -7  M  32.9  2.2 
10 -'  M  31.8  1.6 
This  experiment  was  repeated  three  times  with  PAF  concentrations 
giving secretion varying from 30 to 60%. 
(23), which then acts to induce secretion through a common pathway within the 
platelet. 
The Role of Serine Proteases  in PAF-Induced Secretion.  Secretion from a 
number of 'mediator' cells has  now  been  shown to  involve serine proteases, 
apparently activated during the stimulation process. These include mast cells, 
neutrophils, platelets (see  13), basophils (24), and lymphocytes (25). We have 
now obtained similar evidence for PAF-induced secretion from rabbit platelets 
in that DFP inhibits secretion, but only if present during the reaction. Since 
DFP  is  irreversible  in  its  action  and  pretreatment  of platelets,  or  PAF,  is 
ineffective, activation of a precursor protease on or in the platelets, which only 
then becomes inhibitable with DFP, is suggested. The relative inability of DFP 
to  inhibit  serine  proteases  in  their  zymogen form  is  known  (26i.  The  high 
concentrations of DFP required in this system probably reflect the need for the 
inhibitor to gain access from the outside of  the cell to an enzyme being activated 
in close proximity to its substrate, cleavage of which immediately progresses on 
to secretion. 
Direct evidence for the involvement of such an activatable esterase will have 
to await its isolation and full characterization. Only with the neutrophil enzyme 
involved in chemotaxis has a  substrate for one of these activatable proteases 
involved in cell activation been found (27). In the neutrophil we have shown, 
using [~H]DFP (Becker, E. L. and P. M. Henson, to be published), that as few as 
500-1,000 molecules of such an enzyme may be present per cell. The quantitative PETER  M.  HENSON  AND  ZENAIDA  G.  OADES 
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FIG.  9.  Effect of colchicine and cytochalasin B on PAF-induced secretion. The drugs were 
incubated with platelets for 10 min at 37°C before addition of PAF. 
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problems in isolating the enzyme from neutrophils or platelets will be considera- 
ble. Nevertheless, additional evidence supporting the potential involvement of 
an  activatable  serine  protease  in  PAF-induced platelet  secretion  has  been 
obtained.  Other  inhibitors  of such  enzymes  were  also  active against  PAF- 
induced secretion, including PMSF.  Low molecular weight amino acid esters 
were inhibitory, especially those with basic and aromatic groups.  TAMe was 
most effective of the esters used, and leucine methyl ester was inactive. Substi- 
tution of the  NH2  of lysine methyl ester  (inhibitory),  with  an  acetyl group 
rendered  it  ineffective as  an  inhibitor.  It  is  suggested  that  the  esters  are 
inhibiting the activated enzyme, effectively competing for it with the natural 
intracellular substrate, which is at present unknown. The serine proteases have 
esterolytic activity, and it is important to note that the small molecular weight 
esters  are  significantly more  inhibitory than  the  native  amino  acids.  The 
inhibition is reversible and is not due to hydrolysis products of the esters, since 
methanol itself is  ineffective at  these  concentrations.  While at this  point  it 
cannot be proven that the esters are inhibiting an activatable serine protease, 
the data are consistent with such a hypothesis. 
The  hypothesis that  activation of cells  such  as  platelets,  mast  cells,  and 
neutrophils involves as a very early step the conversion of a precursor protease 
(esterase) to its active form is gaining credence as evidence mounts in its favor 
(13).  We have recently obtained evidence, in addition, that different stimuli 
activate different platelet esterases (23). 
It is possible  that the cell receptor for a  given stimulus and the precursor 
protease are one and the same (or at least are closely linked). If so, the analogy 
between the mechanisms of initiation of two plasma enzyme mediator systems 
(the  complement and coagulation systems) becomes  apparent.  In  both  cases 
presumed  conformational changes  in  precursor  serine  proteases  induced  by 
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man factor) and then to a sequence of amplifying and controlling steps until the 
complement action or coagulation is complete. We are suggesting that a similar 
process,  i.e.  a  conformationally activated protease,  may initiate secretion in 
platelets. Exogenous proteases which activate platelets,  such as thrombin or 
trypsin, might either bypass the enzymes to act on their substrates or could 
themselves activate the putative enzymes. If a  unique enzyme is involved in 
PAF-induced secretion, its decay or inactivation could account for the specific 
desensitization (see the previous paper, 12), as was suggested for the neutrophil 
chemotaxis system (27). If so, the small molecular weight esters may protect 
against the desensitization, as well as providing a possible way of determining 
substrates for the enzymes. 
The Role of Cyclic  Nucleotides  in PAF-Induced Secretion.  Increasing the 
intracellular levels of cAMP in rabbit platelets effectively inhibited the secre- 
tory process. This increase could be brought about by stimulating synthesis of 
cAMP with PgE~ by inhibiting breakdown of the cAMP by the phosphodiester- 
ase with theophylline, or by incubating the platelets with exogenously supplied 
cAMP.  The  effects  of PgE~  and  theophylline in  increasing  cAMP  levels  in 
platelets have been described by others (see 13, 28) and were confirmed by our 
studies.  It  was  also  found,  as  expected  of this  system  (18), that  PgE~  and 
theophylline acted together in a  synergistic manner to prevent PAF-induced 
secretion. 
Cyclic nucleotides, cAMP and cGMP, have been shown to act intracellularly 
to control or initiate secretion from a  wide variety of cells  (see  13). In many 
cases, an antagonistic (Yin Yang) relationship between cAMP and cGMP has 
been demonstrated (29). In cells secreting mediators of inflammatory processes, 
cAMP acts (as seen for PAF-induced secretion) to inhibit the secretory process 
which is somewhat different from its role in other cell types (13). cGMP, on the 
other hand, enhances secretion (30, 31)  or cell movement (32). In the studies 
reported here, however, neither cGMP nor cholinergic agents such as carbachol 
or acetylcholine, which are known to increase levels within cells (29-32),  had 
any effect on the secretion induced by PAF.  We have also observed a  lack of 
effect of the cGMP system on secretion from rabbit platelets induced by other 
stimuli  (unpublished).  The  inference is  that  in this  cell  type,  cAMP  is  the 
modulating nucleotide, and that cGMP and the so called "Yin Yang" effect is 
inoperative. However, increased cGMP has been reported in human platelets 
during collagen-induced secretion (33). Whether this difference from the data 
described herein is a species difference or whether it reflects a lack of action of 
exogenous cGMP or of cholinergic agents is at present unknown. 
If increased levels of cAMP are inhibitory, the question may be raised as to 
how the levels of cAMP change during the secretory process itself. As expected, 
a measurable decrease in the cAMP level was detected. This decrease, although 
time dependent, was extremely rapid,  which is consistent with a  permissive 
effect of the  lowered nucleotide level  on  the  secretory process.  By contrast, 
collagen, which also induces secretion, and in addition, induced lower cAMP 
levels, (as shown also by others, 34) stimulated both of these changes at a slower 
rate.  A  correlative  effect between  changes  in  cAMP  levels  and  secretion  is 
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intracellular cAMP which permits the secretion to occur. When the cAMP levels 
return to normal,  the secretion might then be terminated.  In fact, as described 
in the previous manuscript  (12),  in the case of PAF as a  stimulus, desensitiza- 
tion of platelets by the PAF probably serves to shut off the secretion before the 
cAMP can act.  With other stimuli  for platelet  secretion,  however, the  cAMP 
effect may have more importance. 
The  PAF-induced  desensitization  of platelets  itself  (12)  does not appear  to 
result from changes in cAMP levels for a number of reasons: (a) Increased cAMP 
was  not  observed after  PAF  stimulation.  (b)  The  desensitization  to  PAF  is 
specific for that stimulus. (c) Platelets desensitized to PAF exhibit an enhanced 
secretion  to  other  stimuli.  This  latter  effect was  shown  to  result  from  the 
decreased cAMP levels induced by the original  PAF stimulation. 
The observed decrease in cAMP levels is not extensive  (about 30%),  but is 
consistent with that seen for other stimuli on rabbit platelets (Henson, unpub- 
lished) or with human platelets (34).  Presumably, the balance is very delicate, 
and it does not require much of a decrease to permit secretion to occur. It is also 
possible, though unlikely, that the cAMP is compartmentalized within the cell 
and that a  much greater decrease is occurring within a  particular pool. 
The  measurements  of cAMP  were  made  on  the  whole platelet  population 
(which appears to be relatively homogenous in its response to PAF) including 
the  surrounding  fluid.  A  decrease  thus  represents  increased  destruction  or 
decreased synthesis.  The latter  seems most likely since in human platelets  a 
number of stimuli (including thrombin) are known to inhibit adenylate cyclase. 
It is suggested that the activated serine protease could act similarly on adenyl- 
ate cyclase. In view of the possibility that thrombin might itself be contributing 
to the PAF effect, it is important to emphasize that hirudin,  a potent thrombin 
inhibitor,  did not alter the PAF-induced secretion (1,  10). 
The Role of Microtubules and Microfilaments.  The observation that colchi- 
cine  inhibits  PAF-induced  secretion  suggests  a  role  for  microtubules  in  the 
secretory process. Similar inhibition by colchicine of secretion induced by other 
stimuli has been reported or found (see 17, and Henson, unpublished observa- 
tions). The concentrations of colchicine required are similar to those necessary 
to alter the platelet microtubules as observed by ultrastructural  examination 
(19,  20),  suggesting  that  the  effect is indeed  to 'disrupt'  the  microtubules  or 
rather,  to prevent their subunit aggregation. 
Morphologic observations of the PAF-induced secretion demonstrate a migra- 
tion of the marginal bundle of microtubules towards the center of the platelet as 
described for other stimuli by White (14). Whether this is essential for secretion 
is not known, but if it was, it could explain the effects of colchicine. 
Cytochalasin B enhanced secretion induced by PAF. It also enhances secre- 
tion from human platelets induced by collagen (35). The explanation for this is 
unknown,  although  it is noteworthy that  secretion from neutrophils  (13)  and 
basophils (36) is also enhanced by this drug.  Cytochalasin is thought to disrupt 
the microfilaments  (22), in this case comprised of the contractile protein throm- 
bosthenin.  However, this  has been questioned  (37).  In the  neutrophil,  an  in- 
creased mobility of granules is observed after cytochalasin, probably resulting 
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membrane  (38).  It  is  unclear  whether  a  similar  phenomenon  is operative  in 
platelets.  Cytochalasin B  inhibits  clot retraction  (22),  a  phenomenon  attribut- 
able to platelets and their content of thrombosthenin.  The effect of cytochalasin 
B on secretion from rabbit platelets,  however, has been variable in our hands 
with  different  stimuli.  Thus,  PAF-induced  secretion  is  enhanced,  but  that 
induced by C3 bound to zymosan particles was inhibited (unpublished observa- 
tions).  The  possibility that  these differences might  reflect the  differences be- 
tween a  particulate  or soluble stimulus is under investigation. 
The results suggest some role for both microtubules and microfilaments in the 
secretory process initiated  by PAF.  However, while the  exact mechanism  by 
which  a  stimulus  at  the  platelet  membrane  is  translated  to  a  discharge  of 
granule contents remains unknown in physical, biochemical,  or even morpho- 
logic  terms,  any  suggestions  as  to  the  nature  of the  role  played  by  these 
structural  elements  of the cell  or their  interaction  with  Ca ++  and  cAMP  (39) 
remains highly speculative. 
Condusion.  A  consideration  of all  the  data  would  suggest  that  PAF 
activates a precursor serine protease which then initiates the secretory process 
within the platelet. This latter is a programmed function of the cell and can be 
initiated by other stimuli including collagen, thrombin,  antiplatelet  antibody, 
or C3 (13). Secretion induced by any of these stimuli shows similar properties: is 
calcium and energy requiring, is modulated by cAMP, and in some way involves 
microtubules  and  microfilaments.  A  similar  secretory process  is  observed in 
mast cells and basophils and,  indeed, in neutrophils  and macrophages as well 
(13).  The uniqueness of the reaction lies in the stimulus,  in this case PAF, its 
interaction with cell surface receptor, and its activation of an apparently specific 
serine protease (23). 
Summary 
Secretion  of serotonin  from  platelets  induced  by platelet-activating  factor 
(PAF)  derived  from  antigen-stimulated,  IgE-sensitized  rabbit  basophils  was 
studied  to  further  characterize  the  biochemical  requirements.  Inhibition  of 
secretion with diisopropylphosphofluoridate (DFP) was observed if the DFP was 
present during the reaction, but not ifplatelets or PAF were pretreated with the 
inhibitor.  This suggested a  role for an activatable serine protease in the secre- 
tion. Supporting evidence came from the observation that other protease inhibi- 
tors and a  variety of low molecular weight amino acid esters were also inhibi- 
tory. TAMe was most effective, and AGLMe and LeuMe were inactive, indicat- 
ing  a  specificity  for  different  esters.  Secretion  was  reduced  by  agents  that 
increased  intracellular  cyclic  AMP  (cAMP),  but  enhanced  by  ~-adrenergic 
stimulation,  which reduced the levels of cAMP. Concurrent with PAF-induced 
secretion, a reduction in cAMP levels was observed. No effect of cyclic GMP or 
cholinergic  stimulation  was found.  Secretion  was inhibited  by colchicine  and 
enhanced by cytochalasin B, suggesting a role for microfilaments and microtu- 
bules. The effects of these three systems on PAF-induced secretion indicate the 
basic uniformity of the secretory process in platelets (and other cells) whatever 
the stimulus.  The uniqueness of the reaction apparently lies in the stimulus- 
receptor interaction and the nature of the serine protease which is activated. 
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